Wildfire smoke exposure and early childhood respiratory health: a study of prescription claims data

Radhika Dhingra [1*], Corinna Keeler [2], Brooke S. Staley [2], Hanna V. Jardel [2,3], Cavin Ward-Caviness [3], Meghan E. Rebuli [4,5], Yuzhi Xi [1], Kristen Rappazzo [3], Michelle Hernandez [4], Anne Chelminski [3], Ilona Jaspers [4,5], Ana G. Rappold [3]

[1] Department of Environmental Sciences and Engineering, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

[2] Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

[3] United States Environmental Protection Agency, Center for Public Health and Environmental Assessment, Research Triangle Park, NC, USA.

[4] Department of Pediatrics, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

[5] Center for Environmental Medicine, Asthma, and Lung Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Corresponding Author: Radhika Dhingra, PhD, Department of Environmental Science and Engineering, Gillings School of Global Public Health, University of North Carolina, 135 Dauer Drive, C.B 7431, Chapel Hill, NC 27599. E-mail address: RDhingra@unc.edu

Contributions: RD, MER, and IJ conceived of the study question. AGR, CWC, and IJ obtained study funding. RD, CK, YX, and BSS built the dataset and carried out statistical analyses. KR, AGR, and CW-C advised on statistical analyses and cohort development from claims data. RD classified medications as to the outcome and AC and MH reviewed these classifications. RD, CK, and HVJ drafted the manuscript. All authors revised the manuscript critically for intellectual content, gave final approval of the version to be published, and agreed to be accountable for all aspects of the work.

Declaration: The authors declare they have nothing to disclose.

Funding: Supported by the Environmental Protection Agency (EPA) Cooperative Agreement (U.S. EPA CR83578501); HVJ was supported in part by an appointment to the ORISE participant research program supported by an interagency agreement between EPA and DOE. CK was supported in part by a training grant from the National Institute of Environmental Health Sciences [T32ES007018]. BSS was supported by the Genetic Epidemiology of Heart, Lung, and Blood Traits Training Grant [T32HL129982].

Disclaimer: The views expressed in this article are those of the authors and do not necessarily represent the views or policies of the U.S. Environmental Protection Agency.

Abstract

Wildfire smoke is associated with short-term respiratory outcomes including asthma exacerbation in children. As investigations into developmental wildfire smoke exposure (WSE) on children's longer-term respiratory health are sparse, we investigated associations between developmental WSE and first use of respiratory medications. Prescription claims from IBM MarketScan Commercial Claims and Encounters database were linked with wildfire smoke plume data from NASA satellites based on Metropolitan Statistical Area (MSA). A retrospective cohort of live infants (2010-2016) born into MSAs in six western states, having prescription insurance, and whose birthdate was estimable from claims data was constructed (N=184,703); of these, gestational age was estimated for 113,154 infants. MSA, gestational age, and birthdate were used to estimate average weekly smoke exposure days (*smoke-day*) for each developmental period: three trimesters, and two sequential 12-week periods post-birth. Medications treating respiratory tract inflammation were classified using active ingredient and mode of administration into three categories: : 'upper respiratory', 'lower respiratory', 'systemic anti-inflammatory'. To evaluate associations between WSE and medication usage, Cox models associating smoke-days with first observed prescription of each medication category were adjusted for infant sex, birth-season, and birthyear with a random intercept for MSA. Smoke exposure during postnatal periods was associated with earlier first use of upper respiratory medications (1-12 weeks: hazard ratio (HR)=1.094 per 1-day increase in average weekly smoke-day, 95%CI: (1.005,1.191); 13-24 weeks: HR=1.108, 95%CI: (1.016,1.209)); sex-specific HRs varied by post-birth exposure window. Protective associations were observed during gestational windows for both lower respiratory and systemic anti-inflammatory medications; it is possible that these associations may be a consequence of live-birth bias. These findings suggest WSE during early postnatal developmental periods impact subsequent early life respiratory health.

Introduction

Over the past two decades, frequency and severity of wildfire events has increased, resulting in greater land area being burned each decade (3.3 and 6.8 million average acres per year in 1990s and 2010s, respectively [1]) and substantial economic impact ($347 billion in 2016) that is expected to grow as wildfire frequency increases [2]. Wildfire smoke is a complex chemical mixture of both gases and small particles and a major contributor to $PM_{2.5}$ [3] which has been implicated in over 8.8 million premature deaths worldwide [4].

Particulate matter (PM) exposure during wildfires is associated with acute respiratory and other outcomes in children [5]; in addition, wildfire exposures may increase exacerbation-of-asthma events as indicated by hospitalizations, emergency department visits, and outpatient visits (5). In adults, controlled exposure studies of short-term exposures to woodsmoke have underscored the role of smoke exposure in respiratory dysfunction, and provide evidence of both systemic and respiratory inflammation [7]. In studies of biomass – a primary fuel source for wildfires – burning and woodsmoke, exposure to these pollutants was associated with asthma related symptoms including wheeze in children [8]. Epidemiologic studies [9–14] provide further evidence that wildfire, woodsmoke, and biomass smoke exposures are associated with an increased risk of respiratory infection and reduced lung function in children [15,16] and adults [17–19].

While the acute effects of wildfire or biomass burning exposure have been somewhat established, there is little known about the effects of *in utero* or in early life wildfire particulate matter exposure on longer term respiratory health outcomes. Lung development continues through gestation into the postnatal period, a likely critical window of respiratory susceptibility to air pollution [20]. Additionally, PM exposure during gestation [e.g., 21,22] and early childhood [e.g., 23] is linked to sex-specific respiratory health outcomes in humans [21]. Additional evidence comes from recent studies of non-human primates exposed to wildfire smoke *in utero*, where exposure

to wildfire smoke in the post-natal period resulted in sex-specific attenuation of host-defense

mediators and impaired lung function in adolescence [24].

As similar respiratory effects may also be possible in humans, we consider the research

question: Does exposure to wildfire smoke during gestation or in the early postnatal period result

in earlier first use of respiratory medications in early childhood? By investigating the association

of smoke exposure during multiple developmental periods with first use of respiratory

medication, we identify critical windows of development where exposure to wildfire smoke may

result in increased respiratory vulnerability in the population of young children.

Methods

Population.

We constructed a retrospective cohort of infants from the IBM MarketScan® Commercial

Claims and Encounters Research Database (MarketScan) born into six western U.S. states.

MarketScan is a proprietary deidentified claims database, comprised of data from private U.S.-

based insurance companies. This private claims dataset includes hospitalizations, outpatient

visits, services, and prescription claims data.

Children born between January 1, 2010 and December 31, 2016, in metropolitan statistical

areas (MSAs) in California, Oregon, Washington, Idaho, Montana, or Nevada (**Figure 1**; **Table**

S1) were eligible. Utilizing a validated algorithm [25,26] and ICD-9 or ICD-10 codes, birthdates

were estimated for each live birth (**Appendix 1, Supplementary Material**). The MSA was the

smallest geographic unit available in MarketScan, and therefore the primary spatial unit for

assessing wildfire smoke exposure. Birthdate and MSA were required to estimate exposure to

wildfire smoke for all observations.

111 Each child was required to have continuous enrollment with at least 1 week of prescription

112 coverage starting at birth. For each child, the end of follow-up, measured in weeks, was either

113 date of the outcome, the end date of continuous enrollment, or December 31, 2018, whichever

114 came first. This resulted in two analytic cohorts: the full cohort with 182,387 liveborn children

115 and a sub-cohort with 113,154 liveborn children that also had estimates for gestational age

116 (hereafter, *GA sub-cohort*). This study (IRB No:20-2817) was evaluated and approved by the

117 Institutional Review Board at the University of North Carolina at Chapel Hill.

119 *Gestational age estimation.*

120 Gestational age was used in the GA sub-cohort to estimate with greater precision the

121 average weekly number of smoke exposure days for the portion of each trimester completed. For

122 example, if a child had a GA of 34 weeks, T1 and T2 estimates would be calculated as described

123 above, but T3 would be the average weekly smoke exposure from the 27th week to the end of the

124 34th week.

125 As the MarketScan dataset does not explicitly contain variables for gestational age (GA)

126 at delivery, infant records were linked, where possible, to the birthing parent to allow for GA

127 determination. To estimate GA at birth, we used an algorithm based on ICD-9 codes for the

128 number of completed weeks of gestation, as described in **Appendix 2 (Supplementary**

129 **Material)** [Adapted from 27]; these codes were obtained either from the infants' or the birthing parents'

130 records. Observations with GA were not evenly distributed across time due to the shift from

131 ICD-9 to ICD-10 codes in the fall of 2015. Due to marked changes in GA coding between ICD-9

132 and ICD-10 codes, we chose to estimate GA based on ICD-9 codes only as they were used for

133 the majority of the study period.

Outcome: First use of prescription respiratory medication.

Three outcomes were considered: the first prescription use of (1) upper respiratory, (2)

lower respiratory, and (3) systemic anti-inflammatory medication. Classifications for each of the

three outcomes are briefly summarized in **Table S2**. As systemic anti-inflammatory medications

are often used in acute cases of inflammation that could involve the lower respiratory tract, the

upper respiratory tract or other organ system, we chose to analyze them separately from

medications used more specifically for the upper or lower respiratory tract. If a child was

prescribed medications from two outcome classes on separate or the same claim date, they were

assumed to have the event in analysis of both outcomes. Medications were selected using a

combination of *mode of administration* (*MSTFMDS* variable in MarketScan), *therapeutic drug*

classes (*THERCLS*), and *therapeutic drug groups (THERGRP)* as defined in Micromedex

RedBook [28] in consultation with a pediatric allergist, and referencing Up-To-Date [29]; final

classification of medications were validated by two physicians. The outcome event was defined

as date of the first fill of prescription respiratory medication in outpatient claims.

Exposure: Average weekly wildfire exposure smoke-days.

Wildfire smoke exposure data were obtained from the publicly available NASA satellite

imagery-based Hazard Mapping System Fire and Smoke product [30,31] and were previously used

to generate smoke-day exposure estimates for each ZIP Code Tabulation Area (ZCTA) in the

study area [10]. These data use visible plumes observed via satellite imaging as an approximation

of true wildfire smoke exposure. Using these data, we constructed MSA-level daily smoke-day

exposures as follows: First, we used the official crosswalk files released by the United States

Office of Housing and Urban Development to define membership within an MSA for each

ZCTA in the study area, for each year of the study [32,33]. A MSA was defined as having a smoke-

day on a given date if at least 25% of the population of the MSA experienced a smoke-day,

based on weighting the binary ZCTA smoke-days by year-specific ZCTA population; we refer to

this exposure measurement as the "25% threshold" smoke-day.

In sensitivity analyses, we further examined how estimated proportion of the MSA

population exposed in developing the exposure metric might impact observed associations.

Because each MSA contained a differing number of ZCTAs, we also defined two additional

exposure measures for use in this sensitivity analyses: (1) if any ZCTA within that MSA had a

smoke-day on a given date, the MSA was defined as having a smoke-day on that date [hereafter

referred to as "0% threshold"]; and (3) if 50% of the population of the MSA experienced a

smoke-day on a given date, based on weighting the binary ZCTA smoke-days by year-specific

ZCTA population, the MSA was defined as having a smoke-day on that date [50% threshold].

Thus, the "0% threshold" and "50% threshold" roughly correspond to average weekly smoke-

days experienced by greater than 0% or 50% of the MSA's population, respectively (**Figure 2**).

All analyses were conducted using each of these exposure thresholds, with the 25% threshold

smoke-day exposure utilized in the primary analyses, and the 0% and 50% thresholds applied in

sensitivity analyses.

Smoke-day exposures were linked to each liveborn child according to residential MSA at

birth. For each child, the number of smoke-days were summed in each exposure period and

divided by the number of weeks in the period to produce average weekly smoke-day estimates.

This transformation allows comparison across periods with differing durations and across

individuals with various GAs. Average weekly smoke-day estimates for each period were

generated for each of the three exposure thresholds.

In the full cohort, we estimated the average weekly wildfire smoke-days for the following

time periods: each trimester of gestation, and two consecutive 12-week periods after birth. First,

second, and third trimesters (T1, T2, & T3) were assumed to be 280-197, 196-99, & 98-1 days

before the estimated date of birth, respectively. In the full cohort, postnatal exposure periods, P1

and P2, were defined 1-84 days (1-12 weeks) and 85-168 days (13-24 weeks) after birth,

respectively.

In the GA sub-cohort, we additionally used GA to more accurately estimate the average

weekly smoke-days for the portion of each trimester completed (clarifying example in

Supplementary Material). To distinguish between exposures obtained under the assumption of

40-week gestation (full cohort) and those obtained using estimated GA (GA sub-cohort), we use

the suffix '-40w' or '-GA', respectively.

Statistical Analyses.

For each trimester and postnatal period, mixed effects Cox proportional hazards models

were used to estimate the hazard ratio (HR) for the association between the weekly average

smoke-days and each prescription outcome. Follow-up time was counted in weeks. The

association between average weekly smoke exposure and first use of medications was estimated

using the function below:

$\lambda_{ij}(t) = \lambda_o(t) \, exp[\beta_1 Smoke_{ij} + \beta_2 Sex_{ij} + \beta_3 Birthyear_{ij} + \beta_4 Birth\ Season_{ij} + w_i MSA_i]$ (1)

where $\lambda_{ij}(t)$ is the probability of the first filled respiratory prescription at time *t* for child *j* in the

i^{th} MSA; the *MSA* into which a child was born is the random intercept, and w_i is vector of

coefficients for the random intercept. *Smoke* is the average weekly number of smoke-days for the

given trimester or postnatal period. In addition to the two models of postnatal smoke-day

exposures, separate models were estimated for the six gestational smoke-day exposure periods

(T1-40w, T2-40w, T3-40w, T1-GA, T2-GA, and T3-GA). A proxy for sex-specific hormones

during development, *sex* was dichotomous (male/female). *Birthyear* was included to adjust for

time trends in both the propensity to prescribe medications and the increasing number of smoke-

days. Socioeconomic status was not available in the MarketScan database within which all

children were privately insured. The 4-category covariate *Birth Season*, defined as birth during

Spring (March-May), Summer (June-August), Fall (September-November), or Winter

(December-February), was included to adjust for potential confounding.

Results for each trimester exposure are presented both for full cohort (all eligible births,

assuming a 40-week gestation) and for the GA sub-cohort (the subset of births with estimable

gestational age). Results for each postnatal exposure are presented for the full cohort only.

Hazard ratios (HR (95% confidence interval(CI))) are estimated for a one day increase in weekly

average smoke-days. Results are presented for all children as well as stratified on sex.

Though this analysis focuses on population-level effects rather than specific sub-

populations or etiologies (work-in-progress), we recognize that preterm birth (PTB) that may

drive our main findings. As such, we also stratified by PTB (defined as <37wks) within the GA-

sub-cohort.

RESULTS

Across the study region of 60 MSAs in six western states (U.S.A.), each MSA had

between 31 (Walla Walla, WA) and 24,860 (Los Angeles-Long Beach-Glendale, California)

births recorded in MarketScan during 2010-2016, with mean and median of 3,039 and 914 births

per MSA, respectively (**Table S1**). Los Angeles, Portland, and Seattle contributed the MSAs

with the greatest number of births. Of 182,387 eligible births with estimable birthdates (based on

claims codes summarized in **Appendix 1**), 89,066 (48.8%) were female, and 113,154 (62.0%)

also had an estimable GA (**Table 1**). The number of births per year ranged from 18,578 to

32,721, and the sex distribution remained similar across years. In the full cohort, Cetirizine

hydrochloride (54.3%) and Mometasone furoate (34.8%) were the most frequently filled upper

respiratory prescriptions; Albuterol sulfate (90.0%) was the most frequently filled lower

respiratory prescription; Methylprednisolone, Prednisolone, or Prednisone (86.3%) was the most

frequently filled systemic anti-inflammatory prescriptions (**Table S3**).

On average, children were exposed to less than one day of smoke per week in each

exposure period; the mean trimester exposure ranged from 0.28 to 0.70 weekly smoke-days, and

postnatal mean exposure ranged from 0.37 to 0.74, across the thresholds (**Table S4**). Descriptive

statistics for the full cohort, the GA sub-cohort and those without GA were relatively comparable

(**Table S5**).

Postnatal period.

In both the first (P1) and second (P2) postnatal periods, the models reflected an

association between smoke-day exposure with earlier first use of upper respiratory medication

(P1: HR=1.094 per 1-day increase in weekly smoke-day (1.005, 1.191); P2: HR=1.108 (1.016,

1.209)); **Figure 3**, **Table 2**). In the P1 period, female children had the larger effect size and

stronger association (HR=1.123 (0.994, 1.27)) as compared to males (HR=1.055 (0.940, 1.185)).

In contrast, male children had a larger effect size (HR=1.128 (1.004, 1.266)) and stronger

association in P2, as compared to female children (HR=1.072 (0.942, 1.22); **Figure 3**, **Table 2**).

Associations in primary models (i.e., using the 25% threshold) of lower respiratory as well as

systemic anti-inflammatory outcomes were largely null (**Figure 3**, **Table 2**).

Gestational period

Positive associations with smoke exposure were observed only in the first trimester for
the upper respiratory outcome. The 40w- and GA- exposure models produced HRs in the same
direction with comparable magnitude, and with some variation in precision (**Figure 3**, **Table 3**).

Upper respiratory. In the primary model, the impact of smoke-days on the upper
respiratory medications outcome varied by gestational period, with increased risk in the first
trimester, and null or decreased risk in the second and third trimester (**Figure 3**, **Table 3**). In the
first trimester, smoke-day exposure was associated with shorter times to first upper respiratory
medication, among all (HR=1.082 (0.985, 1.188)), and female children (HR=1.140 (0.997,
1.303)) among the full cohort (T1-40w), but not in male children (HR=1.026 (0.902, 1.167);
Figure 3); these first trimester HRs are comparable in the GA sub-cohort (T1-GA), albeit with
less precision in the 95%CI. For all other exposure windows, generally null associations were
consistently observed in both the full cohort and the GA sub-cohort.

Lower respiratory. Smoke-days had a null or slightly inverse association across all three
trimesters in the 40-week exposure modeled in both the full cohort and the GA sub-cohort
(**Figure 3, Table 3**). In contrast to first trimester upper respiratory outcome findings, first
trimester smoke-day exposure among the full cohort (T1-40w) was associated with delayed first
lower respiratory medications among all (HR=0.977 (0.951, 1.003)) and male children
(HR=0.960 (0.927, 0.993)), but not in female children (HR=0.997 (0.956, 1.039); **Figure 3**).

Systemic Anti-inflammatory. Second trimester smoke-day exposures in the GA sub-cohort
(T2-GA) were inversely associated with longer time to the use of systemic anti-inflammatory
medication in all (HR=0.946 (0.905, 0.989)) and male (HR=0.921 (0.869, 0.987)) children
(**Figure 3**, **Table 3**). Similar, but smaller magnitude associations were observed in the first

trimester (T1-GA) (All: HR=0.962 (0.927, 0.997); male: HR=0.959 (0.914, 1.006); **Figure 3**)).

Interestingly, a similar protective association was found among female children in the third

trimester (T3-GA) (HR=0.935 (0.892, 0.992)), but not among male children. In the full cohort,

the exposures across all trimesters and groups produce consistent and similarly precise

associations that are closer to the null than their counterparts in the GA sub-cohort.

Sensitivity analyses

In the postnatal period, HRs and 95%CIs for both upper respiratory and systemic anti-

inflammatory outcomes are approximately similar across the 0%, 25% and 50% exposure

thresholds (**Figure S1**). For the lower respiratory outcome, however, results in the exposure

sensitivity analyses are more variable across thresholds.

For all trimester outcomes, the various thresholds used to generate smoke-day exposure

estimates generally had little effect on HR estimates, with some marginal changes in the

confidence interval precision (**Figure S1**). HR did not markedly differ between term births and

PTBs.

DISCUSSION

Using private insurance claims data, we conducted a time-to-event analysis to estimate

the association between developmental exposure to wildfire smoke and first use of respiratory

medication. We found an association between smoke exposure during the first trimester, and

both postnatal periods with shorter time to first use of upper respiratory medication; these results

were robust across exposure definitions. This positive association between wildfire exposure and

upper respiratory medication used was larger for female children in the first trimester and the

first 12-week postnatal period, while it was stronger for male children in the 13-24 postnatal

week period. These stratified results may suggest sex-specific windows of vulnerability.

Additionally, for both systemic anti-inflammatory medication and lower respiratory

medication, protective effects of wildfire exposure were observed during most gestational

windows. Most prominently, we observed a shorter time to first lower respiratory medication use

among male children and all children during the first trimester; this finding was relatively

consistent across cohort specification (i.e., full cohort vs GA sub-cohort). Similarly, all children

and male children had shorter times to first systemic anti-inflammatory medication with

increased smoke exposure during the first and second trimesters; this was true also of girls in the

first trimester. Whether the mechanism for these observed protective effects is an artifact of

observational epidemiology or a causal biological finding cannot be ascertained in this dataset.

Our findings suggest a complex epidemiological relationship between gestational

exposure to wildfire smoke and time to first symptoms requiring respiratory prescription use.

The juxtaposition of below-null HRs during gestation with evidence in the literature suggesting

that ambient air pollution is not protective indicates that this analysis may suffer from selection

bias (as do most perinatal epidemiological studies [34]). In administrative datasets, these analyses

are necessarily limited to live births, and do not capture pregnancy loss. If the *in utero* response

to wildfire smoke exposure is strong, restricting the cohort to live births could lead to attrition of

susceptible pregnancies and to an *in utero*-outcome association which is biased to appear less

harmful or even protective. Indeed, non-human primate work shows pregnancy loss is associated

with wildfire smoke exposure [35].

The differing exposure pathways in the gestational and postnatal periods could also

account for the discrepancy in findings between these two developmental windows. Broadly,

possible pathways for air pollutants to exert influence on a fetus include altered placentation or

placenta-mediated processes, and direct fetal exposure. Recent work showed that PM can deposit

in placental tissue and, to a lesser extent, pass through the placenta to fetal capillaries [36–38]. The

increased tidal volume in the birthing parent as well as the increased respiratory rate in young

children may result in a larger dose of air pollutants [39,40]. Should this increased deposition of

wildfire smoke pollutants in the birthing parent impair placentation, there may be increased fetal

loss as observed in non-human primates and mentioned above [35]. In the surviving fetuses,

however, our inconsistent or null findings in the gestational period as compared to positive upper

respiratory postnatal findings, could indicate that direct exposure to nasal epithelia, as occurs in

the postnatal period, produces a more prominent and detectable increase in use of respiratory

medications.

Previous studies of PM exposures suggest specific respiratory conditions that could result

from wildfire smoke exposure, and may or may not require prescriptions treatment. For example,

developmental exposures to PM or biomass burning are associated with early life deficits in lung

function [41–43], and increased susceptibility to acute respiratory infection (ARI) or infant

bronchiolitis [44,45]. While ARI is often treated with prescription medication in young children,

subclinical deficits in lung function associated with developmental air pollution exposure may

not always be identified and treated with prescription medication unless they lead to respiratory

infection [21,43,46–51]. It is possible that study cohort members experienced respiratory symptoms

that were transient, sub-clinical or well-managed with non-prescription medication, and thus

were not captured in this analysis blunting any potential association.

Because lung development occurs in phases starting in early gestation and continuing into

adolescence, damage in early life may have lasting negative effects. As PM is a component of

wildfire smoke exposure, the mechanisms by which such negative effects occur likely include a

combination of oxidative stress and inflammation, which may further induce physiological [52–54]

or epigenetic changes in the birthing parent and/or offspring [55,56]. Early gestational exposure may

lead to abnormal cellular differentiation or branching due to a disruption of essential redox

signaling [52], while later exposure may induce structural or functional abnormalities [53,54]. In non-

human primates, early life exposure to woodsmoke has been linked to reduced lung function

metrics [24] which may be due to epigenetic changes to respiratory tissues [57].

To our knowledge, this is the first analysis describing the impact of exposure to wildfire

smoke during development on prescription-treated respiratory conditions in human children.

There are several additional strengths in this analysis. We were able to represent multiple

exposure scenarios by using various thresholds for assigning smoke-days to an MSA. For

example, because the definition of smoke-day is based on the appearance of a plume from

satellite data, adjacent areas may indeed be exposed to a lower level of smoke that, while not

visible, is still impactful; this scenario is captured by the 0% threshold. We also explored

refining exposure estimate using GA. Despite losing 38% of the dataset by including claims-

based estimates of GA, exaggerated effect estimates observed in the GA sub-cohort suggest that

accounting for GA captures important aspects of exposure relative to fetal development that the

assumption of 40-week gestation does not. The use of prescription claims data more accurately

captures medication usage than diagnosis or prescription delivery captured in electronic medical

records. Further the thorough categorization of these medications by two physicians ensures that

they are meaningfully classified. Finally, we were the first to leverage two widely used datasets

to answer our research question: well-vetted wildfire exposure data and private claims data able

to capture prescription usage.

First use of respiratory prescription medication as described in a private insurance claims

database serves as an indicator of respiratory health and vulnerability; this approach is not

without limitations. The MarketScan Commercial Claims and Encounters database is limited by

omission of those who are not on private insurance and those living in rural areas; this could

make our results less generalizable to other groups because of socioeconomic factors. While the

Marketscan claims database allows the examination of a large population distributed over a large

wildfire-impacted region, the availability of individual-level confounders, such as race, SES, and

maternal or second-hand smoking, is unfortunately limited. As observed with other air pollutant

exposures (31), SES could modify the effect of smoke exposure on respiratory health. Relatedly,

this analysis assumes that all participants are exposed to the same proportion of outdoor air

pollution (e.g., that they spend the same amount of time outside and all have the same/no indoor

air purification systems), which may contribute to the potential for exposure bias differential on

SES or other related factors.

Imprecision in the estimates of residence may lead to exposure misclassification, though

this impact is expected to be small given the size of a MSA in which exposures are defined as

uniform due to the spatial coarseness of the data. MSA at birth provides a relatively coarse

estimate of exposure which could be improved upon by using a dataset which includes more

granular residential information. We also assumed that the MSA at time of birth was the same

during the entirety of gestation; while likely not universally true, the impact of this assumption is

expected to be small with potential bias toward the null (32,33). Additionally, the coarseness of

gestational age available in the ICD-9 coding system, wherein codes are available at 2-week

intervals between 24-37 weeks (inclusive), somewhat limits the accuracy of our exposure

estimates in the GA sub-cohort; such exposure misclassification may also induce bias in the

effect estimates. Finally, some respiratory outcomes may be lost by claims data, as it is only able

to provide information on conditions treated by prescription for those who have access to

necessary care.

The modest differences in associations by sex found in this analysis contribute to

growing evidence supporting sex-differential effects of wildfire smoke exposure. There are well-

documented sex differences in lung development and asthma [58], including stress-induced

oxidative response among fetuses [59]. Noted sex-specific reductions in lung function in non-

human primates following wildfire smoke exposure during infancy [24] may be exacerbated by

prenatal PM exposure [21].

Overall, these findings suggest that first trimester and postnatal wildfire smoke exposure

is associated with shorter time to the first upper respiratory medication usage, while gestational

wildfire smoke exposure across trimesters is associated with longer time to systemic anti-

inflammatory respiratory prescription usage. This research supports the growing body of

literature indicating that wildfire smoke exposure in early life poses a health risk for pediatric

populations, and adds granularity to the current understanding of sex-specific and trimester-

specific effects of in utero wildfire smoke exposure. Clinicians may consider discussing the

potential benefits of reducing exposure using evidenced-based measures such as observing air

quality index alerts, placing air purifiers in their home, and wearing face masks to reduce

particulate exposures. Future work should investigate specific clinical outcomes, such as acute

respiratory infection, and utilize finer spatial and temporal granularity to refine estimates of

wildfire smoke exposure. This work also highlights the continued need to evaluate measures to

protect against wildfire smoke during key developmental stages.

References

1. National Interagency Fire Center. *Total Wildland Fires and Acres (1983-2021)*. Accessed March 24, 2022. https://www.nifc.gov/fire-information/statistics/wildfires

2. Fann N, Alman B, Broome RA, et al. The health impacts and economic value of wildland fire episodes in the U.S.: 2008–2012. *Sci Total Environ*. 2018;610-611:802-809. doi:10.1016/j.scitotenv.2017.08.024

3. Liu JC, Peng RD. The impact of wildfire smoke on compositions of fine particulate matter by ecoregion in the Western US. *J Expo Sci Environ Epidemiol*. 2019;29(6):765-776. doi:10.1038/s41370-018-0064-7

4. Lelieveld J, Pozzer A, Pöschl U, Fnais M, Haines A, Münzel T. Loss of life expectancy from air pollution compared to other risk factors: a worldwide perspective. *Cardiovasc Res*. 2020;116(11):1910-1917. doi:10.1093/cvr/cvaa025

5. Künzli N, Avol E, Wu J, et al. Health effects of the 2003 Southern California wildfires on children. *Am J Respir Crit Care Med*. 2006;174(11):1221-1228. doi:10.1164/rccm.200604-519OC

6. Reid CE, Maestas MM. Wildfire smoke exposure under climate change: impact on respiratory health of affected communities. *Curr Opin Pulm Med*. 2019;25(2):179-187. doi:10.1097/MCP.0000000000000552

7. Rebuli ME, Speen AM, Martin EM, et al. Wood Smoke Exposure Alters Human Inflammatory Responses to Viral Infection in a Sex-Specific Manner. A Randomized, Placebo-controlled Study. *Am J Respir Crit Care Med*. 2019;199(8):996-1007. doi:10.1164/rccm.201807-1287OC

8. Sigsgaard T, Forsberg B, Annesi-Maesano I, et al. Health impacts of anthropogenic biomass burning in the developed world. *Eur Respir J*. 2015;46(6):1577-1588. doi:10.1183/13993003.01865-2014

9. DeFlorio-Barker S, Crooks J, Reyes J, Rappold AG. Cardiopulmonary Effects of Fine Particulate Matter Exposure among Older Adults, during Wildfire and Non-Wildfire Periods, in the United States 2008-2010. *Environ Health Perspect*. 2019;127(3):37006. doi:10.1289/EHP3860

10. Wettstein ZS, Hoshiko S, Fahimi J, Harrison RJ, Cascio WE, Rappold AG. Cardiovascular and Cerebrovascular Emergency Department Visits Associated With Wildfire Smoke Exposure in California in 2015. *J Am Heart Assoc*. 2018;7(8):e007492. doi:10.1161/JAHA.117.007492

11. Rappold AG, Stone SL, Cascio WE, et al. Peat bog wildfire smoke exposure in rural North Carolina is associated with cardiopulmonary emergency department visits assessed through syndromic surveillance. *Environ Health Perspect*. 2011;119(10):1415-1420. doi:10.1289/ehp.1003206

12. Haikerwal A, Akram M, Del Monaco A, et al. Impact of Fine Particulate Matter (PM2.5)
Exposure During Wildfires on Cardiovascular Health Outcomes. *J Am Heart Assoc*.
2015;4(7):e001653. doi:10.1161/JAHA.114.001653

13. Morgan G, Sheppeard V, Khalaj B, et al. Effects of bushfire smoke on daily mortality and
hospital admissions in Sydney, Australia. *Epidemiol Camb Mass*. 2010;21(1):47-55.
doi:10.1097/EDE.0b013e3181c15d5a

14. Delfino RJ, Brummel S, Wu J, et al. The relationship of respiratory and cardiovascular
hospital admissions to the southern California wildfires of 2003. *Occup Environ Med*.
2009;66(3):189-197. doi:10.1136/oem.2008.041376

15. Mishra V. Indoor air pollution from biomass combustion and acute respiratory illness in
preschool age children in Zimbabwe. *Int J Epidemiol*. 2003;32(5):847-853.
doi:10.1093/ije/dyg240

16. Oloyede IP, Ekrikpo UE, Ekanem EE. Lung Function Indices of Children Exposed to Wood
Smoke in a Fishing Port in South-South Nigeria. *J Trop Pediatr*. 2013;59(5):399-402.
doi:10.1093/tropej/fmt033

17. Fullerton DG, Suseno A, Semple S, et al. Wood smoke exposure, poverty and impaired lung
function in Malawian adults. *Int J Tuberc Lung Dis*. 2011;15(3):391-398.

18. García-Sancho MC, García-García L, Báez-Saldaña R, et al. Indoor pollution as an
occupational risk factor for tuberculosis among women: a population-based, gender oriented,
case-control study in Southern Mexico. :8.

19. Pérez-Padilla R, Pérez-Guzmán C, Báez-Saldaña R, Torres-Cruz A. Cooking with biomass
stoves and tuberculosis: a case control study. *Int J Tuberc Lung Dis Off J Int Union Tuberc*
Lung Dis. 2001;5(5):441-447.

20. Wright RJ, Brunst KJ. Programming of respiratory health in childhood: influence of outdoor
air pollution. *Curr Opin Pediatr*. 2013;25(2):232-239. doi:10.1097/MOP.0b013e32835e78cc

21. Hsu HL, Chiu YM, Coull BA, et al. Prenatal Particulate Air Pollution and Asthma Onset in
Urban Children. Identifying Sensitive Windows and Sex Differences. *Am J Respir Crit Care*
Med. 2015;192(9):1052-1059. doi:10.1164/rccm.201504-0658OC

22. Stapleton A, Casas M, García J, et al. Associations between pre- and postnatal exposure to
air pollution and lung health in children and assessment of CC16 as a potential mediator.
Environ Res. 2022;204:111900. doi:10.1016/j.envres.2021.111900

23. Schultz ES, Hallberg J, Bellander T, et al. Early-Life Exposure to Traffic-related Air
Pollution and Lung Function in Adolescence. *Am J Respir Crit Care Med*. 2016;193(2):171-
177. doi:10.1164/rccm.201505-0928OC

24. Black C, Gerriets JE, Fontaine JH, et al. Early Life Wildfire Smoke Exposure Is Associated
with Immune Dysregulation and Lung Function Decrements in Adolescence. *Am J Respir*
Cell Mol Biol. 2017;56(5):657-666. doi:10.1165/rcmb.2016-0380OC

25. Li L, Jick S, Breitenstein S, Hernandez G, Michel A, Vizcaya D. Pulmonary arterial
hypertension in the USA: an epidemiological study in a large insured pediatric population.
Pulm Circ. 2017;7(1):126-136. doi:10.1086/690007

26. Li Q, Andrade SE, Cooper WO, et al. Validation of an algorithm to estimate gestational age
in electronic health plan databases. *Pharmacoepidemiol Drug Saf*. 2013;22(5):524-532.
doi:10.1002/pds.3407

27. Butler AM, Layton JB, Li D, et al. Predictors of Low Uptake of Prenatal Tetanus Toxoid,
Reduced Diphtheria Toxoid, and Acellular Pertussis Immunization in Privately Insured
Women in the United States. *Obstet Gynecol*. 2017;129(4):629-637.
doi:10.1097/AOG.0000000000001927

28. Truven Health Analytics/IBM Watson Health. IBM Micromedex RedBook. Published 2021.
https://www.micromedexsolutions.com

29. Up To Date. Up To Date.

30. Rolph GD, Draxler RR, Stein AF, et al. Description and Verification of the NOAA Smoke
Forecasting System: The 2007 Fire Season. *Weather Forecast*. 2009;24(2):361-378.
doi:10.1175/2008WAF2222165.1

31. Schroeder W, Ruminski M, Csiszar I, et al. Validation analyses of an operational fire
monitoring product: The Hazard Mapping System. *Int J Remote Sens*. 2008;29(20):6059-
6066. doi:10.1080/01431160802235845

32. OFFICE OF POLICY DEVELOPMENT AND RESEARCH (PD&R). HUD USPS ZIP
CODE CROSSWALK FILES. Accessed November 12, 2021.
https://www.huduser.gov/portal/datasets/usps_crosswalk.html#data

33. Wilson, Ron, Din, Alexander. Understanding and Enhancing the U.S. Department of
Housing and Urban Development's ZIP Code Crosswalk Files. *Cityscape J Policy Dev Res*.
20(2):277-294.

34. Snowden JM, Bovbjerg ML, Dissanayake M, Basso O. The curse of the perinatal
epidemiologist: inferring causation amidst selection. *Curr Epidemiol Rep*. 2018;5(4):379-
387. doi:10.1007/s40471-018-0172-x

35. Willson BE, Gee NA, Willits NH, et al. Effects of the 2018 Camp Fire on birth outcomes in
non-human primates: Case-control study. *Reprod Toxicol*. 2021;105:128-135.
doi:10.1016/j.reprotox.2021.08.005

36. Bongaerts E, Nawrot TS, Van Pee T, Ameloot M, Bové H. Translocation of (ultra)fine
particles and nanoparticles across the placenta; a systematic review on the evidence of in

vitro, ex vivo, and in vivo studies. *Part Fibre Toxicol*. 2020;17(1):56. doi:10.1186/s12989-020-00386-8

37. Bongaerts E, Aengenheister L, Dugershaw BB, et al. Label-free detection of uptake, accumulation, and translocation of diesel exhaust particles in ex vivo perfused human placenta. *J Nanobiotechnology*. 2021;19(1):144. doi:10.1186/s12951-021-00886-5

38. Engelen L. Translocation of airborne black carbon particles from mother to unborn child: an ENVIRONAGE birth cohort study. :29.

39. Chang J, Streitman D. Physiologic Adaptations to Pregnancy. *Neurol Clin*. 2012;30(3):781-789. doi:10.1016/j.ncl.2012.05.001

40. Fleming S, Thompson M, Stevens R, et al. Normal ranges of heart rate and respiratory rate in children from birth to 18 years: a systematic review of observational studies. *Lancet*. 2011;377(9770):1011-1018. doi:10.1016/S0140-6736(10)62226-X

41. Bai H, Capitanio JP, Miller LA, Clougherty JE. Social status and susceptibility to wildfire smoke among outdoor-housed female rhesus monkeys: A natural experiment. *Heliyon*. 2021;7(11):e08333. doi:10.1016/j.heliyon.2021.e08333

42. Schultz ES, Gruzieva O, Bellander T, et al. Traffic-related Air Pollution and Lung Function in Children at 8 Years of Age: A Birth Cohort Study. *Am J Respir Crit Care Med*. 2012;186(12):1286-1291. doi:10.1164/rccm.201206-1045OC

43. Jedrychowski WA, Perera FP, Spengler JD, et al. Intrauterine exposure to fine particulate matter as a risk factor for increased susceptibility to acute broncho-pulmonary infections in early childhood. *Int J Hyg Environ Health*. 2013;216(4):395-401. doi:10.1016/j.ijheh.2012.12.014

44. Odo DB, Yang IA, Knibbs LD. A Systematic Review and Appraisal of Epidemiological Studies on Household Fuel Use and Its Health Effects Using Demographic and Health Surveys. *Int J Environ Res Public Health*. 2021;18(4):1411. doi:10.3390/ijerph18041411

45. Karr C, Demers P, Koehoorn M. Influence of ambient air pollutant sources on clinical encounters for infant bronchiolitis. *Am J Respir Crit Care Med*. 2009;180:995-1001.

46. Seeni I, Ha S, Nobles C, Liu D, Sherman S, Mendola P. Air pollution exposure during pregnancy: maternal asthma and neonatal respiratory outcomes. *Ann Epidemiol*. 2018;28(9):612-618.e4. doi:10.1016/j.annepidem.2018.06.003

47. Rosa MJ, Just AC, Kloog I, et al. Prenatal particulate matter exposure and wheeze in Mexican children: Effect modification by prenatal psychosocial stress. *Ann Allergy Asthma Immunol*. 2017;119(3):232-237.e1. doi:10.1016/j.anai.2017.06.016

48. Chiu YHM, Coull BA, Sternthal MJ, et al. Effects of prenatal community violence and ambient air pollution on childhood wheeze in an urban population. *J Allergy Clin Immunol*. 2014;133(3):713-722.e4. doi:10.1016/j.jaci.2013.09.023

49. Soh SE, Goh A, Teoh OH, et al. Pregnancy Trimester-Specific Exposure to Ambient Air
Pollution and Child Respiratory Health Outcomes in the First 2 Years of Life: Effect
Modification by Maternal Pre-Pregnancy BMI. *Int J Environ Res Public Health*.
2018;15(5):996. doi:10.3390/ijerph15050996

50. Latzin P, Röösli M, Huss A, Kuehni CE, Frey U. Air pollution during pregnancy and lung
function in newborns: a birth cohort study. *Eur Respir J*. 2009;33(3):594-603.
doi:10.1183/09031936.00084008

51. Jedrychowski WA, Perera FP, Maugeri U, et al. Effect of prenatal exposure to fine
particulate matter on ventilatory lung function of preschool children of non-smoking
mothers. *Paediatr Perinat Epidemiol*. 2010;24(5):492-501. doi:10.1111/j.1365-
3016.2010.01136.x

52. Land SC, Wilson SM. Redox Regulation of Lung Development and Perinatal Lung
Epithelial Function. *Antioxid Redox Signal*. 2005;7(1-2):92-107. doi:10.1089/ars.2005.7.92

53. Kajekar R. Environmental factors and developmental outcomes in the lung. *Pharmacol Ther*.
2007;114(2):129-145. doi:10.1016/j.pharmthera.2007.01.011

54. Korten I, Ramsey K, Latzin P. Air pollution during pregnancy and lung development in the
child. *Paediatr Respir Rev*. 2017;21:38-46. doi:10.1016/j.prrv.2016.08.008

55. Dugershaw BB, Aengenheister L, Hansen SSK, Hougaard KS, Buerki-Thurnherr T. Recent
insights on indirect mechanisms in developmental toxicity of nanomaterials. *Part Fibre
Toxicol*. 2020;17(1):31. doi:10.1186/s12989-020-00359-x

56. Veras MM, de Oliveira Alves N, Fajersztajn L, Saldiva P. Before the first breath: prenatal
exposures to air pollution and lung development. *Cell Tissue Res*. 2017;367(3):445-455.
doi:10.1007/s00441-016-2509-4

57. Brown AP, Cai L, Laufer BI, Miller LA, LaSalle JM, Ji H. Long-term effects of wildfire
smoke exposure during early life on the nasal epigenome in rhesus macaques. *Environ Int*.
2022;158:106993. doi:10.1016/j.envint.2021.106993

58. Carey MA, Card JW, Voltz JW, et al. It's all about sex: gender, lung development and lung
disease. *Trends Endocrinol Metab*. 2007;18(8):308-313. doi:10.1016/j.tem.2007.08.003

59. Minghetti L, Greco A, Zanardo V, Suppiej A. Early-life sex-dependent vulnerability to
oxidative stress: the natural twining model. *J Matern Fetal Neonatal Med*. 2013;26(3):259-
262. doi:10.3109/14767058.2012.733751

Tables

Table 1. *Cohort composition in the full cohort and the gestational age sub-cohort, overall and by sex.*

	Full cohort			Gestational age sub-cohort		
	ALL CHILDREN (N = 182,387)	MALE CHILDREN (N=93,321)	FEMALE CHILDREN (N = 89,066)	ALL CHILDREN (N = 113,154)	MALE CHILDREN (N=57,682)	FEMALE CHILDREN (N=55,472)
Birth Season						
Spring	50,733 (27.8%)	26,128 (28.0%)	24,605 (27.6%)	32,269 (28.5%)	16,546 (28.7%)	15,723 (28.3%)
Summer	50,290 (27.6%)	25,801 (27.6%)	24,489 (27.5%)	31,858 (28.2%)	16,345 (28.4%)	15,513 (28.0%)
Fall	44,777 (24.6%)	22,708 (24.3%)	22,069 (24.8%)	26,338 (23.3%)	13,294 (23.1%)	13,044 (23.5%)
Winter	36,587 (20.1%)	18,684 (20.0%)	17,903 (20.1%)	22,689 (20.1%)	11,497 (20.0%)	11,192 (20.2%)
Birth Year						
2010	25,031 (13.7%)	12,513 (13.4%)	12,518 (14.1%)	15,391 (13.6%)	7,614 (13.2%)	7,777 (14.0%)
2011	27,143 (14.9%)	13,841 (14.8%)	13,302 (14.9%)	18,203 (16.1%)	9,225 (16.0%)	8,978 (16.2%)
2012	32,721 (17.9%)	16,736 (17.9%)	15,985 (17.9%)	23,127 (20.4%)	11,780 (20.5%)	11,347 (20.5%)
2013	32,438 (17.8%)	16,686 (17.9%)	15,752 (17.7%)	23,343 (20.6%)	11,924 (20.7%)	11,419 (20.6%)
2014	27,543 (15.1%)	14,196 (15.2%)	13,347 (15.0%)	21,279 (18.8%)	11,003 (19.1%)	10,276 (18.5%)
2015	18,933 (10.4%)	9,833 (10.5%)	9,100 (10.2%)	11,811 (10.4%)	6,136 (10.7%)	5,675 (10.2%)
2016	18,578 (10.2%)	9,516 (10.2%)	9,062 (10.2%)	-	-	-
Gestational Age						
less than 28 wks	449 (0.2%)	237 (0.3%)	212 (0.2%)	449 (0.4%)	237 (0.4%)	212 (0.4%)
28 to 36 wks	8,433 (4.6%)	4,396 (4.7%)	4,037 (4.5%)	8,433 (7.5%)	4,396 (7.6%)	4,037 (7.3%)
greater than 36 wks	104,216 (57.1%)	53,049 (56.8%)	51,223 (57.5%)	104,216 (92.1%)	53,049 (92.1%)	51,223 (92.3%)
missing	69,289 (38%)	35,639 (38.2%)	33,594 (37.7%)	-	-	-
Upper respiratory medication claim						
No	179,939 (98.7%)	91,935 (98.5%)	88,004 (98.8%)	111,752 (98.8%)	56,880 (98.8%)	54,872 (98.9%)
Yes	2,448 (1.3%)	1,386 (1.5%)	1,062 (1.2%)	1,402 (1.2%)	802 (1.4%)	600 (1.1%)
Lower respiratory medication claim						
No	148,646 (81.5%)	73,668 (78.9%)	74,978 (84.2%)	92,707 (81.9%)	45,810 (79.6%)	46,897 (84.5%)
Yes	33,741 (18.5%)	19,653 (21.1%)	14,088 (15.8%)	20,447 (18.1%)	11,872 (20.6%)	8,575 (15.5%)
Systemic anti-inflammatory medication claim						
No	158,348 (86.8%)	79,068 (84.7%)	79,280 (89.0%)	98,549 (87.1%)	49,048 (85.2%)	49,501 (89.2%)
Yes	24,039 (13.2%)	14,253 (15.3%)	9,786 (11%)	14,605 (12.9%)	8,634 (15%)	5,971 (10.8%)

Table 2. *Mixed effects cox model of smoke exposure during post-partum trimester at the 25% exposure threshold, in all eligible children and stratified by sex. P1 and P2 periods correspond to 0-12 and 13-24 weeks, respectively. Models are adjusted for birth-season, birthyear and, where applicable, sex, with a random intercept for MSA. All exposures are the average weekly number of smoke-days in the given post-partum period. RX = prescribed medication claim.*

	Exposure	ALL CHILDREN (N = 182,387) HR (95% CI)	MALE CHILDREN (N = 93,321) HR (95% CI)	FEMALE CHILDREN (N = 89,066) HR (95% CI)
Upper respiratory RX	P1	1.094 (1.005, 1.191)	1.055 (0.940, 1.185)	1.123 (0.994, 1.270)
	P2	1.108 (1.016, 1.209)	1.128 (1.004, 1.266)	1.072 (0.942, 1.220)
Lower respiratory RX	P1	1.007 (0.983, 1.031)	1.013 (0.982, 1.045)	0.992 (0.955, 1.030)
	P2	0.980 (0.955, 1.007)	0.971 (0.938, 1.005)	0.987 (0.947, 1.029)
Systemic Anti-inflammatory RX	P1	1.001 (0.975, 1.028)	0.995 (0.961, 1.030)	1.008 (0.966, 1.051)
	P2	0.996 (0.969, 1.025)	1.004 (0.968, 1.042)	0.980 (0.938, 1.025)

Table 3. *Mixed effects cox model results of smoke exposure during gestational periods at the 25% exposure threshold, in all eligible children and stratified by sex. Models are adjusted for birth season, birthyear and, where applicable, sex, with a random intercept for MSA. The first and second N values correspond to the entire cohort (full cohort) and the cohort portion whose gestational age estimate was available to estimate wildfire smoke-day exposure (GA sub-cohort), respectively. All exposures are the average weekly number of smoke-days in the given period. RX = prescribed medication claim.*

Outcome	Cohort	Exposure	ALL CHILDREN (N = 182,387 / 113,154) HR (95% CI)	MALE CHILDREN (N = 93,321 / 57,682) HR (95% CI)	FEMALE CHILDREN (N = 89,066 / 55,472) HR (95% CI)
Upper respiratory RX	Full cohort				
		T1	1.082 (0.985, 1.188)	1.026 (0.902, 1.167)	1.140 (0.997, 1.303)
		T2	0.978 (0.876, 1.093)	1.079 (0.935, 1.245)	0.857 (0.722, 1.018)
		T3	0.913 (0.821, 1.014)	0.884 (0.766, 1.020)	0.948 (0.812, 1.107)
Upper respiratory RX	GA sub-cohort				
		T1	1.094 (0.974, 1.229)	1.066 (0.910, 1.249)	1.121 (0.949, 1.324)
		T2	0.935 (0.806, 1.085)	0.978 (0.806, 1.186)	0.882 (0.701, 1.108)
		T3	0.948 (0.833, 1.080)	0.957 (0.804, 1.140)	0.931 (0.770, 1.127)
Lower respiratory RX	Full cohort				
		T1	0.977 (0.951, 1.003)	0.960 (0.927, 0.993)	0.997 (0.956, 1.039)
		T2	0.986 (0.957, 1.017)	0.987 (0.949, 1.027)	0.978 (0.933, 1.026)
		T3	0.992 (0.966, 1.019)	1.004 (0.969, 1.040)	0.970 (0.930, 1.012)
Lower respiratory RX	GA sub-cohort				
		T1	0.966 (0.935, 0.999)	0.959 (0.918, 1.002)	0.969 (0.920, 1.021)
		T2	0.968 (0.930, 1.008)	0.966 (0.917, 1.018)	0.962 (0.903, 1.025)
		T3	0.972 (0.939, 1.005)	0.982 (0.940, 1.027)	0.948 (0.899, 1.000)
Systemic Anti-inflam. RX	Full cohort				
		T1	0.976 (0.948, 1.005)	0.978 (0.941, 1.016)	0.973 (0.929, 1.018)
		T2	0.968 (0.935, 1.001)	0.967 (0.925, 1.010)	0.967 (0.916, 1.020)
		T3	0.996 (0.966, 1.027)	1.008 (0.968, 1.049)	0.975 (0.930, 1.022)
Systemic Anti-inflam. RX	GA sub-cohort				
		T1	0.962 (0.927, 0.997)	0.959 (0.914, 1.006)	0.963 (0.910, 1.019)
		T2	0.946 (0.905, 0.989)	0.921 (0.869, 0.976)	0.982 (0.917, 1.053)
		T3	0.989 (0.953, 1.027)	1.024 (0.975, 1.075)	0.935 (0.882, 0.992)

Figure Captions

Figure 1. Cohort construction. WA, OR, CA, MT, NV, and ID refer to the states of Washington, Oregon, California, Montana, Nevada, and Idaho, respectively. MSA is Metropolitan Statistical Area and CONUS is Continental United States.

Figure 2. Spatial distribution of total number of smoke-days (2010-2016) at each MSA for the (a) 0%, (b) 25%, and (c) 50% thresholds. Thresholds are defined as the population-weighted percentage of zip codes within an MSA required to experience a smoke-day, in order to assign a smoke-day to the MSA.

Figure 3. Hazard ratio and confidence intervals for the relationship of average weekly smoke-days and first use of prescription outcome, in each averaging period at the 25% exposure threshold, for all children (green square), and within strata of male children (purple diamonds) and female children (orange circle). The Cox proportional hazards models were adjusted for birth season, birth year, infant sex and included a random intercept for metropolitan statistical area; infant sex covariate was omitted in infant sex-stratified models. rx = prescribed medication claim; T1-T3 refer to the first-third trimesters; P1 and P2 refer to the first and second 12-week post-natal period.

a

b

c

Total smoke days
- 70 or fewer
- 71-140
- 141-210
- 211-350
- more than 350